You are here

Diabetes and Vascular Disease Research

Diabetes and Vascular Disease Research


eISSN: 17528984 | ISSN: 14791641 | Current volume: 17 | Current issue: 4 Frequency: Bi-monthly

Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title. Diabetes & Vascular Disease Research is an open access journal.

It mirrors the increasing recognition that diabetes and cardiovascular disease are a single entity in which diabetes and related disorders, such as insulin resistance, are directly linked with assaults on the vessel wall and the development of vascular risk clustering.

Diabetes & Vascular Disease Research:

  • Links diabetes, its metabolic consequences and vascular outcomes
  • Original research in fields of insulin resistance and metabolic disorders
  • Promotes understanding of pathology, aetiology and management of thrombosis, hyperglycaemia, hypertension, dyslipidaemia and micro- and macrovascular consequences.

This journal is a member of the Committee on Publication Ethics (COPE)

Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons licence. The APC for this journal is currently 750 USD, discounted from the full rate of 1,500 USD for a limited time. 

The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here

This journal changed its publication mode from subscription to open access in January 2020.

Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title. Diabetes & Vascular Disease Research is an open access journal.  

It mirrors the increasing recognition that diabetes and cardiovascular disease are a single entity in which diabetes and related disorders, such as insulin resistance, are directly linked with assaults on the vessel wall and the development of vascular risk clustering.

Diabetes & Vascular Disease Research:

  • Links diabetes, its metabolic consequences and vascular outcomes
  • Original research in fields of insulin resistance and metabolic disorders
  • Promotes understanding of pathology, aetiology and management of thrombosis, hyperglycaemia, hypertension, dyslipidaemia and micro- and macrovascular consequences.
Editor in Chief
Peter Grant University of Leeds, UK
Diabetes Editor
Clifford J Bailey Aston University, UK
Vascular Disease Editor
Nikolaus Marx University of Aachen, Germany
Clinical Trials Editor
Darren McGuire University of Texas Southwestern Medical Centre, USA
Pre-clinical Research Editor
Mark Cooper Monash University, Austalia
Assistant Editors
Richard Cubbon University of Leeds, UK
Stefano Del Prato University of Pisa, Italy
Odette Gore University of Texas Southwestern Medical Center, USA
Silvio Inzucchi Yale University School of Medicine, USA
Florian Kahles Harvard Medical School, USA
Steve Marso Saint Luke's Hospital, USA
Linda Mellbin Karolinska Institute, Sweden
Bianca Rocca Catholic University School of Medicine, Italy
David Russell Leeds Teaching Hospitals NHS Trust and University of Leeds, UK
Ann Marie Schmidt Columbia University, USA
Associate Editor
Ramzi Ajjan Leeds University, UK
Florian Kahles Harvard Medical School, USA
Editorial Assistant
Vicki Harper Leeds University, UK
Editorial Board
George Alberti Newcastle University Medical School, UK
Carlos Alvarez University of Texas, Southwestern Medical Center, USA
Lina Badimon Hospital de la Santa Creu I Sant Pau, Spain
Cora Beckers University of Leeds, UK
Angelyn Bethel University of Oxford, UK
Ian De Boer University of Washington, USA
Antonio Ceriello Warwick University, UK
Mansoor Husain University of Toronto, Canada
Eri Toda Kato Brigham and Women's Hospital, USA
Mark Kearney Leeds University, UK
Mikhail Kosiborod Saint Luke's Mid America Heart Institute, USA
Andrew J Krentz University of Bedfordshire, UK
Lawrence A. Leiter St Michael's Hospital, Canada
Peter Libby Brigham and Women's Hospital, USA
Ildiko Lingvay University of Texas, Southwestern Medical Center, USA
John Nolan St James' Hospital, Ireland
John Petrie University of Glasgow, UK
Carolyn Lam Su Ping National University Heart Centre, Singapore
Jorge Plutzky Harvard Medical School, USA
Paul M Ridker Brigham & Women's Hospital, USA
Lars Ryden Karolinska University Hospital, Sweden
Katharina Schütt University Hospital Aachen, RWTH University, Germany
Ulf Smith The Sahlgrenska Academy, Sweden
Bart Staels Universiti Lille Nord de France, France
E Standl Diabetes Research Institute, Germany
George Steiner WHO Collaborative Center, Canada
J E Tooke Peninsula Medical School, UK
Harvey White University of Pittsburgh School of Medicine, USA
Paul Zimmet International Diabetes Insitute, Australia
  • EMBASE/Excerpta Medica
  • Index Medicus
  • Index Medicus (Ceased 2004)
  • MEDLINE
  • ProQuest
  • Scopus
  • Manuscript Submission Guidelines: Diabetes and Vascular Disease Research

    Table of Contents:

    1. Open Access
    2. Article Processing Charge
    3. What Do We Publish
      3.1 Aims and Scope
      3.2 Article Types
      3.3 Writing Your Paper
    4. Editorial Policies
      4.1 Peer Review Policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical Trials
      4.8 Reporting Guidelines
      4.9 Research Data
    5. Publishing Policies
      5.1 Publication Ethics
      5.2 Contributor’s Publishing Agreement
    6. Preparing Your Manuscript
      6.1 Formatting
      6.2 Artwork, figures and other graphics
      6.3 Supplemental material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting Your Manuscript
      7.1 How to submit your manuscript
      7.2 Title, keywords and abstracts
      7.3 ORCID
      7.4 Information required for completing your submission
      7.5 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Online Publication
      8.3 Promoting your article
    9. Further Information
    10. Appealing the publication decision

     

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/dvdres to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

    Only manuscripts of sufficient quality that meet the aims and scope of Diabetes and Vascular Disease Research will be reviewed. As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    Diabetes and Vascular Disease Research may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy.

    If your paper is accepted, you must include a link on your preprint to the final version of your paper.

    If you have any questions about publishing with SAGE, please visit the SAGE Journal Solutions Portal

    1. Open Access

    Diabetes and Vascular Disease Research is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

    Back to top

    2. Article Processing Charge

    If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license.

    An introductory article processing charge (APC) of $750, discounted from the full rate of $1500, is available for a limited time.

    The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.

    Back to top

    3. What Do We Publish

    3.1 Aims and Scope

    Before submitting your manuscript to Diabetes and Vascular Disease Research, please ensure you have read the Aims & Scope.

    3.2 Article Types

    The journal publishes original papers, reviews, discussions of topical issues, case studies and meeting reports. The suggested word counts only refer to the body of the text and exclude references etc.

    Summary of manuscript structure

    Title page (title of article, author names - forename, initials, surname - author affiliations, author for correspondence - title, address, telephone and fax numbers, email). Sole author articles should be accompanied by a relatively recent photograph of the author (at least 55 mm x 70 mm in size and at a minimum resolution of 300 dpi).

    Originals, Reviews, Achieving Best Practice, Current Topics: Abstract 200 words, max. Key Words 6 max.; Abbreviations and Acronyms box (do not write in full in text); Key Messages 5 max.; Subheaded text, to include an Introduction and Conclusion/Discussion; References (ideally max. 30); Vancouver - <4 authors cite all, >4 authors cite first 3 et al.; Ref title. Journal year,vol:pages. Provide web addresses and month accessed. Tables - ideally submitted in Word. Figures - ideally submitted in PowerPoint using journal colours (pinks/maroon/grey) which can be modified to journal pantones by Production. Font styles should be consistent across all submitted figures. All figures and tables require legends and keys/abbreviations as appropriate. Photographs/Images - original image saved as .tiff or .eps file (minimum resolution 300 dpi), see section 9.4.3 for more details.

    Short Reports: These are important preliminary data that justify early publication or briefer studies that warrant a short communication. Normally these manuscripts would be 1,500 words with 10-12 references and one figure or table.

    Editorials, Case studies: As above but omit Abstract, Key Words and Key Messages.

    Manuscripts should be structured as listed below.

    Original papers

    Should include:

    • Title page.

    • Abstract (200 words): a short inclusive statement suitable for direct electronic abstracting identifying the purpose of the study, key methods, the main results and the main conclusion.

    • Key words: maximum of 6 key words for indexing.

    • Introduction: concise description of background, sufficient for the non-specialist to appreciate the context of the work. Clear statement of the purpose of the study.

    • Methods: a brief description of study design, procedures, analytical techniques and statistical evaluation.

    • Results: a clear account of the study findings using quantitative language where possible and cross-referenced to tables and figures (ideally in PowerPoint using journal colours).

    • Discussion: an interpretation of the study placed within the context of current knowledge leading to specific conclusions where possible.

    • Each of the above sections should use subheadings as appropriate

    • Acknowledgements.

    • References (ideally max. 30), figures and tables (see 9.4.3 for more details)

    Reviews, Achieving Best Practice and Current Topics

    Should include:

    • Title page as above. Abbreviations & Acronyms box as necessary.

    • Abstract (200 words): setting out the scope, key messages and conclusions of the review.

    • Body of text: liberally partitioned with headings and subheadings leading to a synopsis with conclusions at the end.

    Reviews ~2,500 words; Ach Best Pract 1,000-2,000 words; Curr Top 500-1,500 words

    Should include:

    • Key messages: in a separate box itemising 2-5 very short principal points.

    • Acknowledgements.

    • References (ideally max. 30), figures and tables (see 9.4.3 for more details).

    Editorial

    Should include:

    • Title page as above. Abbreviations & Acronyms box as necessary.

    • Body of text: 500-2,500 words, liberally partitioned with headings and subheadings leading to a synopsis with conclusions at the end.

    • References (ideally max. 30), figures and tables (see 9.4.3 for more details).

    Case Study

    Should include:

    • Title page as above. Abbreviations & Acronyms box if necessary - if abbreviations only used once, write in full in text.

    • Introduction/case history as appropriate (see published studies). 200-500 words. Succinct Conclusion/Discussion containing the key learning points provided by the case  If you are considering a longer Case study please follow all guidance for an Achieving Best Practice article.

    • Photograph/Image (original image saved as .tiff or .eps file - minimum resolution of 300 dpi - for scanned photographs see 9.4.3).

    • References (ideally max. 5), photographs, figures and tables (see 9.4.3 for more details).

    If you would like to discuss your paper prior to submission contact the Editor-in-Chief (p.j.grant@leeds.ac.uk) or Editor’s Assistant (V.L.Harper@leeds.ac.uk).

    3.3 Writing Your Paper

    The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.

    3.3.1 Making your article discoverable

    For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online

    Back to top

    4. Editorial Policies

    4.1 Peer Review Policy

    The journal’s policy is to have manuscripts reviewed by two expert reviewers. Diabetes and Vascular Disease Research utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Manuscripts are initially assigned to either the Editor-in-Chief who will make a decision regarding whether the manuscript fits within the aims and scope of the journal and is of sufficient priority to warrant peer review. At this stage some manuscripts may be immediately rejected. Papers which pass this initial check will then be assigned to either the Editor-in-Chief or a Section Editor who will manage the assignment of peer reviewers; each manuscript is reviewed by at least two referees. The Section Editor will then make a recommendation to the Editor-in-Chief regarding publication, primarily based on the reviewers comments. The Editor-in-Chief will make his final decision based on both this recommendation and the comments of the reviewers.

    As part of the submission process you will be asked to provide the names of peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below: 

    • The reviewer should have no prior knowledge of your submission
    • The reviewer should not have recently collaborated with any of the authors
    • Reviewer nominees from the same institution as any of the authors are not permitted

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite/ reject any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor / Board member will have no involvement in the decision-making process.

    Diabetes and Vascular Disease Research is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for Journal Title can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
    2. Drafted the article or revised it critically for important intellectual content,
    3. Approved the version to be published,
    4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    4.3.1 Third party submissions
    Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:

    •    Disclose this type of editorial assistance – including the individual’s name, company and level of input 
    •    Identify any entities that paid for this assistance 
    •    Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.

    Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.

    4.3.2 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

     

    4.4 Funding

    Diabetes and Vascular Disease Research requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

    4.5 Declaration of conflicting interests

    It is the policy of Diabetes and Vascular Disease Research to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    4.7 Clinical trials

    Diabetes and Vascular Disease Research conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    4.9 Research Data

    At SAGE we are committed to facilitating openness, transparency and reproducibility of research. Where relevant, Diabetes and Vascular Disease Research encourages authors to share their research data in a suitable public repository subject to ethical considerations and to include a data accessibility statement in their manuscript file. Authors should also follow data citation principles. For more information please visit the SAGE Author Gateway, which includes information about SAGE’s partnership with the data repository Figshare.

    Back to top

    5. Publishing Policies

    5.1 Publication Ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism

    Diabetes and Vascular Disease Research and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    5.2 Contributor’s Publishing Agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Diabetes and Vascular Disease Research publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.

    Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.

    Back to top

    6. Preparing your manuscript

    6.1 Formatting

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    6.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines  

    Figures supplied in color will appear in color online.

    6.3 Supplemental Material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplemental files.

    6.4 Reference Style

    Diabetes and Vascular Disease Research adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the SAGE Vancouver EndNote output file.

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    7. Submitting Your Manuscript

    7.1 How to submit your manuscript

    Diabetes and Vascular Disease Research is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. http://mc.manuscriptcentral.com/dvdres to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    7.2 Title, keywords and abstracts

    Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.

    7.3 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

    The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.

    7.4 Information required for completing your submission

    Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed on the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    7.5 Permissions

    Please ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Journal Author Gateway.

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.

    8.2 Online Publication

    One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

    8.3 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.

    Back to top

    9. Further Information

    Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Diabetes and Vascular Disease Research editorial office as follows:

    Vicki Harper
    Editorial Assistant

    mailto:V.L.Harper@Leeds.ac.uk

    Back to top

    10. Appealing the publication decision

    Editors have very broad discretion in determining whether an article is an appropriate fit for their journal. Many manuscripts are declined with a very general statement of the rejection decision. These decisions are not eligible for formal appeal unless the author believes the decision to reject the manuscript was based on an error in the review of the article, in which case the author may appeal the decision by providing the Editor with a detailed written description of the error they believe occurred.

    If an author believes the decision regarding their manuscript was affected by a publication ethics breach, the author may contact the publisher with a detailed written description of their concern, and information supporting the concern, at publication_ethics@sagepub.com

     

    Back to top